MedPath

Clinical Evaluation of LightSheer Duet 805nm HS Handpiece

Not Applicable
Completed
Conditions
Hair Removal
Interventions
Device: LightSheer Duet HS handpiece
Registration Number
NCT01801202
Lead Sponsor
Lumenis Be Ltd.
Brief Summary

* The study will re-confirm that the LightSheer Duet HS 805 nm handpiece is safe for removal of unwanted hair, and will result in hair removal and permanent hair count reduction.

* Twenty (20)subjects, Fitzpatrick Skin Type I-IV will be included in a single site.

* Each subject will receive five treatments at four to six week intervals and return for follow-up visits at three and six months after the last treatment for evaluation of the treated areas.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  1. Able to read, understand and provide written Informed Consent;
  2. Healthy adult, male or female, 18 years of age or older with skin type I-IV;
  3. Having a suitable treatment area for hair removal;
  4. Able and willing to comply with the treatment/follow-up schedule and requirements;
  5. Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control at least three months prior to enrollment and throughout the course of the study.
Exclusion Criteria
  1. Pregnant, expectation of pregnancy, postpartum or nursing (<6 months);
  2. Hormonal disorders that may affect hair growth;
  3. Immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications;
  4. Livedo reticularis;
  5. Uncontrolled systemic diseases such as diabetes;
  6. Active infections in the treated area;
  7. Dysplastic nevi;
  8. Significant concurrent skin conditions or any inflammatory skin conditions;
  9. Active cold sores, open lacerations or abrasions;
  10. Chronic or cutaneous viral, fungal, or bacterial diseases;
  11. Current cancer;
  12. History of skin cancer or pre-cancerous lesions at the treatment areas;
  13. Use of Accutaneâ„¢ (Isotretinoin) within the past six month;
  14. Keloid formation in the treatment area;
  15. Tattoos in the treatment area;
  16. Bleeding coagulopathies or use of anticoagulants;
  17. Auto-immune disorders;
  18. Erythema ab igne, when identified treatments should be discontinued;
  19. Photosensitivity disorder that can be exacerbated by laser or intense light;
  20. Herpes simplex in the treatment area;
  21. Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light;
  22. Poor wound healing;
  23. Sunburns;
  24. Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a week) and during the course of the evaluation;
  25. Prior skin treatment with laser or other devices on the same treated areas within the last six months prior to study enrollment or during the course of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Hair removalLightSheer Duet HS handpiecehair removal treatment using 805nm LightSheer Duet HS handpiece
Primary Outcome Measures
NameTimeMethod
Hair count6 monts follow up

To verify hair removal and permanent hair reduction using the LightSheer Duet HS 805 nm handpiece

Number of subjects with Adverse Events1 year

To evaluate the safety of hair removal using the LightSheer Duet HS 805 nm handpiece

Secondary Outcome Measures
NameTimeMethod
Subject's comfort using VASBaseline, 4, 8, 12, 16 weeks;

To evaluate subject's assessment of comfort associated with treatments

Asses subject's perception of improvement and satisfaction8, 16 weeks following baseline; 3 and 6 monts follow up

To evaluate subject's satisfaction with hair removal treatments and assessment of improvement using subject's questionnaire

Trial Locations

Locations (1)

Laser & Skin Surgery Medical Group Inc

🇺🇸

Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath